---
title: Mannitol Versus Supportive Care in Ciguatera Fish Poisoning
nct_id: NCT02570971
overall_status: UNKNOWN
phase: PHASE3
sponsor: University of South Florida
study_type: INTERVENTIONAL
primary_condition: Ciguatoxin
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02570971.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02570971"
ct_last_update_post_date: 2015-10-07
last_seen_at: "2026-05-12T06:34:11.713Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Mannitol Versus Supportive Care in Ciguatera Fish Poisoning

**Official Title:** Mannitol Versus Supportive Care in Ciguatera Fish Poisoning: A Randomized Control Trial

**NCT ID:** [NCT02570971](https://clinicaltrials.gov/study/NCT02570971)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** University of South Florida
- **Collaborators:** Florida Poison Control Center
- **Conditions:** Ciguatoxin
- **Start Date:** 2015-10
- **CT.gov Last Update:** 2015-10-07

## Brief Summary

Ciguatera poisoning, caused by the ingestion of ciguatoxin-containing fish, is a global public health concern. In the US, the vast majority of ciguatera poisonings occur in Florida, followed by Hawaii and California. Equipoise exists in the medical literature regarding the effectiveness of mannitol therapy in treatment of ciguatera poisoning. While there are many case reports attesting to its utility, the only randomized control trial (RCT) comparing mannitol therapy with supportive care failed to show any significant benefit from mannitol treatment for a variety of clinical outcomes. Investigators therefore propose a second, larger RCT to test this question.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 100 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* History consistent with ciguatera poisoning

Exclusion Criteria:

* Minors
* pregnant patients
* those unable to give consent
* severe congestive heart failure or renal failure
```

## Arms

- **Control** (NO_INTERVENTION) — Patients will receive supportive care measures.
- **Investigational** (EXPERIMENTAL) — Patients will receive 500mL of 20% mannitol

## Interventions

- **Mannitol** (DRUG)

## Primary Outcomes

- **Symptom score** _(time frame: 24 hours)_ — Covers a variety of neurological and gastrointestinal symptoms on a 0-4 score

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02570971.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02570971*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*